Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

ErbB4 (Her4) Monoclonal Antibody (HFR1), eBioscience™, Invitrogen™

Mouse Monoclonal Antibody

$240.00 - $1562.00

Specifications

Antigen ErbB4 (Her4)
Clone HFR1
Concentration 0.5 mg/mL
Classification Monoclonal
Conjugate Unconjugated
View More Specs

Products 2
Catalog Number Mfr. No. Quantity Price Quantity & Availability  
Catalog Number Mfr. No. Quantity Price Quantity & Availability  
14-968-780
Encompass_Preferred
View Documents
Invitrogen™
14968780
25 μg
Each for $240.00
Only null left
Edge
Add to Cart
 
14-968-737
Encompass_Preferred
View Documents
Invitrogen™
14968737
2 mg
Each for $1,562.00
Only null left
Add to Cart
 
Description

Description

The MAb HFR1 recognizes human and mouse epidermal growth factor receptor 4 (ErbB4 or HER4). ErbB4 belongs to the family of receptor tyrosine kinases (RTK) of which HER1 (EGRF), HER2 (ErbB2), and HER3 (ErbB3) are members. RTKs function to affect a variety of cell processes including proliferation, differentiation, migration, survival and apoptosis and are often disregulated in cancer. The ErbB4 protein contains extracellular ligand binding domains, a transmembrane region, and a cytoplasmic tail containing the tyrosine kinase domain and the binding site for the HFR1 antibody. Upon ligand binding, ErbB4 homo- or hetero-dimerizes with other family members, becomes phosphorylated, and can be cleaved allowing translocation to the nucleus. The HRF1 antibody recognizes membrane-bound, cytoplasmic and nuclear ErbB4. Cytosolic ErbB4 expression was found to correlate with a positive prognosis in a subset of breast cancer patients, while nuclear ErbB4 expression was inversely correlated with tumor grade and aggressiveness of breast tumors.

Oncogene ERBB4 (HER4) is a member of the type I receptor protein tyrosine subfamily that includes EGFR, ERBB2, and ERBB3. ERBB4 binds and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. ErbB 4 is activated by neuregulins and NTAK (neural and thymus derived activator for ErbB kinases). ErbB 4 is a receptor for heregulin and is capable of mediating HGL-stimulated tyrosine phosphorylation of itself. Like other protein kinases, ErbB 4 mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. ErbB 4 is most predominantly expressed in several breast carcinoma cell lines, and in normal skeletal muscle, heart, pituitary, brain, and cerebellum. Breast tumor cell lines T47-D, MDA-MB-453, BT-474 and H3396 are found to have the highest levels of mRNA, and intermediate levels are seen in MCF-7, MDAMB-330 and MDA-MB-361. Expression of ErbB 4 is low or absent in some breast tumor cell lines such as MDA-MB-231, MDA-MB-157, MDA-MB-468, and SKBR-3. ErbB 4 levels have been found to be elevated in certain human tumor cell lines suggesting that it may play a role in some malignancies.
Specifications

Specifications

ErbB4 (Her4)
0.5 mg/mL
Unconjugated
Mouse
Human, Mouse
Q15303, Q61527
IgG2b κ
Affinity Chromatography
Antibody
HFR1
Monoclonal
Liquid
RUO
PBS with 0.09% sodium azide; pH 7.2
13869, 2066
Primary
4°C
ERBB4
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.